Serum samples from 103 blood donors or patients with slightly increased serum levels of liver enzymes were tested for antibodies to hepatitis C virus (anti-HCV) using second generation tests and for HCV RNA by the polymerase chain reaction (PCR). PCR was in a nested configuration, using primer pairs
Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors
✍ Scribed by Peter H. McGuinness; G. Alex Bishop; Alfred Lien; Brenton Wiley; Carolyn Parsons; Geoffrey W. McCaughan
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 665 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
Approximately 90% of subjects with chronic hepatitis resulting from hepatitis C virus infection have hepatitis C virus RNA in serum. However, the prevalence of hepatitis C virus RNA in serum from subjects with hepatitis C virus antibody associated with persistent normal liver biochemical values is unclear. Do these subjects have resolved or continuing infection with hepatitis C virus? The aim of this study was to examine whether subjects with hepatitis C virus antibody but normal ALT levels had evidence of ongoing infection. Our study population was divided into four groups. Groups 1,2 and 3 comprised hepatitis C virus antibody-positive volunteer blood donors. Group 1 was made up of subjects found to be hepatitis C virus antibody-positive on enzyme-linked immunosorbent assay with persistent abnormal ALT levels (59 donors: 53 positive on recombinant immunoblot assay and 6 indeterminate). Group 2 members were hepatitis C virus antibody positive, with persistent normal ALT levels (50 donors: 39 positive on recombinant immunoblot assay and 11 indeterminate). Group 3 members were hepatitis C virus seropositive but negative on second-generation recombinant immunoblot assay (n = 48). Twenty patients (not blood donors) with chronic liver disease who were anti-hepatitis C virus seronegative were used as controls (group 4). Serum samples from all four groups were assayed for hepatitis C virus RNA on reverse transcription and a 40-cycle polymerase chain reaction with a combination of primers from the highly conserved 5'-noncoding and less-conserved third and fourth nonstructural regions. All assays were confirmed on hybridization with an internal probe. In group 1,55 of 59 subjects (93.2%) had hepatitis C virus RNA in serum. In group 2, 21 of 50 subjects (42%) had hepatitis C virus RNA in serum. Twenty-one of the 39 recombinant immunoblot assaypositive subjects (53.9%) had hepatitis C virus RNA, compared with none of the 11 recombinant immunoblot assay-indeterminant subjects (p = 0.001 on f assay). In recombinant immunoblot assay-positive subjects with normal ALT readings less than 1 mo
📜 SIMILAR VOLUMES
## Abstract Of 103,203 donations collected in Scotland and Northern Ireland over a 3‐month period and screened for HCV antibody by Ortho or Abbott second‐generation ELISAs, 340 were found repeatedly reactive. Supplementary testing with RIBA‐2 resulted in 77 being classified as positive, 130 as inde
## Abstract Hepatitis C virus (HCV) requires reverse transcriptase‐polymerase chain reaction (RT‐PCR) or branched DNA signal amplification assays to be detected in patient samples. Although conventional methods of RNA isolation are employed for samples of serum, plasma, and peripheral blood mononuc
Hepatitis C virus (HCV) is the predominant cause of parenterally transmitted non-A, non-B (NANB) hepatitis worldwide (1, 2). Although the clinical manifestations of acute HCV infection are often relatively mild, persistent infection is a frequent outcome and is associated with significant risk of pr
## Abstract The low specificity of screening ELISAs for antibodies to hepatitis C virus in blood donors has called for confirmatory tests. Two types of supplementary antibody assays are available, recombinant immunoblot assays (RIBA‐1 and RIBA‐2) and an antibody consumption test referred to as a ne